Shattuck Labs Commences Public Offering of Stock and Warrants
STTK has more than doubled off its 52-week low of $0.712 on elevated volume (2.1× avg).
Summary
Shattuck Labs has commenced a public offering of common stock or pre-funded warrants, with underwriters having an option for an additional 15%. This capital raise is being conducted under an existing shelf registration filed in January 2026. While the offering provides crucial funding for the clinical-stage biotech, it will result in dilution for current shareholders. This follows recent warrant exercises that generated $54.9 million and the company's Q1 net loss, despite an extended cash runway into 2029.
At the time of this announcement, STTK was trading at $4.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $327.4M. The 52-week trading range was $0.71 to $8.33. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.